Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
En zo kabbelen we het jaar uit en het nieuwe in met rond de €2,50 op de borden. Spektakel in 2017? Voorspoedig nieuwjaar gewenst aan de particuliere Onxeo aandeelhouders.
www.businesswire.com/news/home/201703... Onxeo: Full-year 2016 Results and Outlook for 2017 Reinforcement of Onxeo’s strategic positioning in the development of innovative oncology treatments Acquisition of DNA Therapeutics and the AsiDNATM product, a first-in-class candidate in the new area of preventing tumor cells from repairing their DNA Enrolment for the phase III Livatag® study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Cash and cash equivalents of €29.2 million at December 31, 2016, providing financial visibility through to 2018.
globenewswire.com/news-release/2017/0... Onxeo announces allowance of U.S. patent for Livatag® in hepatocellular carcinoma USPTO Notice of Allowance received for patent related to specific route of administration for Livatag® provides protection of related claims until 2032 SharePrint May 10, 2017 13:17 ET | Source: Onxeo S.A. PARIS, May 10, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the specific route of administration for Livatag®, which is currently in a phase III clinical trial (ReLive) for the second-line treatment of hepatocellular carcinoma (primary liver cancer). Livatag® (doxorubicin Transdrug™) is based on an innovative technology allowing the formulation of doxorubicin (a chemotherapeutic agent) within nanoparticles composed of polyalkylcyanoacrylate, cyclodextrin, and poloxamer. This nanoparticle formulation provides new and promising properties, including overcoming the mechanisms of chemoresistance developed by tumor cells that affect the efficacy of chemotherapy agents. “The United States represents a significant target market for Livatag®. This new U.S. patent significantly strengthens our Livatag® intellectual property portfolio, and enhances the value of this late-stage product candidate. We look forward to the availability of data from our ReLive trial in mid-2017,” said Judith Greciet, CEO of Onxeo. The new patent provides protection of the associated claims in the U.S. until 2032, and is in addition to the previously issued patents for the same patent family in other major territories, such as Europe and Japan. An additional patent family has also been filed based on a specific composition of Livatag® nanoparticles that, if granted, would extend the patent protection of Livatag® to 2036.
3.34 +0.43 (14.78%) Meestal na opleving goed nieuws zakt het weer in, het lijkt nu redelijk stabiel.
men had weer eens meer verwacht
peebee schreef op 24 mei 2017 09:19 :
en weer één positief DSMB... de 10e
www.onxeo.com/en/onxeo-announces-10th... vanzelfsprekend zeer positieve referentie voor Onxeo (Livatag) vanuit onafhankelijke Europese raad. Ik kocht 2 weken geleden al bij op basis van gemiddeld gestegen volume en positieve nieuws flow. Kwestie van weken voor mijn gevoel dat koers hogere toppen gaat neer zetten. We zullen nog even geduld moeten hebben, heb dit er graag voor over!
Jammer dat ze niet langer het aantal toegediende doses Livatag vermelden. Is toch een aardige indicator vwv werkzaamheid
3.70 +0.43 (13.15%) Is dit nog op het nieuws van afgelopen week? Ik kan niets nieuws vinden.
4.47 +1.20 (36.70%) krijg de neiging om wat te verkopen, maar ook last van FOMO. edit: kwart eruit gedaan op 4.40 edit: en nog een kwart eruit op 4.25. Met doel om lager terug te kopen.
Dit is de enige info die ik kan vinden, een analisten rapport (via boursarama.com)www.boursorama.com/forum-onxeo-ex-bio... markt voor Livitag 800 Miljoen. Lijkt erop dat dit mensen wakker heeft gemaakt. Huidige market cap ca. 200 miljoen (na de stijging van vandaag) ONXEO Council Image: pics-investir.lesechos.com/images/btn... invest Booked subscriber ONXEO - FR0010095596 / Paris PEA SRD real time quotation PARIS - 05/25/17 - 17H 35mn 16s 1, 87% 3,270 € (c) Buy Sell The right time to build on success COURSES NEWS RECOMMENDATIONS HISTORY SOCIETY FORUM INVEST IR.FR | LE 26/05/17 AT 08:04 | UPDATED 26/05/17 At 08:47 This biotech will soon know the results of a major interim study on its flagship product. Revenues are estimated at € 800 million in the future by an analyst firm in case of success. Image: https: // invest. Leechos.fr/medias/2017/05/25/1680006_1495718884_1657311-149060 4644-shutterstock-397168636-min_565x377p.jpg The right time to build on success | Photo credits: Shutterstock The right time to build on success | Photo credit: Shutterstock Analysis (Invest) Another milestone for Biotech Onxeo and its flagship product, Livatag, is an advanced form of liver cancer that has few therapeutic options. The former BioAlliance, which merged with the Danish Topotarget in 2014, obtained a tenth positive recommendation from the safety and monitoring committee (data safety monitoring board, an independent committee responsible for assessing safety every six months) A clinical study) for the ongoing phase III study for Livatag. No changes to the study were requested, nor was there any specific comment to be made by the committee. For Oddo Securities, "this announcement is obviously good news as it comes to reassure on the security profile of the product that was for some time problematic. Indeed, the DSMB decided in 2008 to suspend phase II of Livatag because of the acute respiratory side effects observed at the time in the patients. Onxeo has since solved this problem by developing a new system of administration that has drastically reduced these risks. " And this new tenth recommendation is all the more positive because it comes" a few weeks of a major catalyst in terms of news flow for Onxeo with the publication of the interim results of phase III for its most important assets Livatag, "Continues the research firm. In the model developed by Oddo, it is 800 million euros of income that is at stake if successful, which could be facilitated by the fact that it is an orphan disease, which very often increases The chances of homologation. By way of comparison, the market capitalization of Onxeo is only 154 million euros. These interim results are expected by mid-2017. The biotech has enough cash by then, more than 12 million euros, that is to say a fortnight of financial visibility. ADVERTISING At 3.28 euros, the share has climbed by 31% since the beginning of the year and rebounded by 65% ??compared to its historic low of just a year ago. But it was worth more than 11 euros in February 2014. DL The board The upside is very important in case of success. It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file. The course at the time of the advice: 3.27 € More about investir.lesechos.fr/actions/conseil-... r-un-succes-1680006. php # P3jtk41b8lxhMkDK.99 The share has climbed by 31% since the beginning of the year and rebounded by 65% ??compared to its historic low of just a year ago. But it was worth more than 11 euros in February 2014. DL The board The upside is very important in case of success. It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file. The course at the time of the advice: 3.27 € More about investir.lesechos.fr/actions/conseil-... r-un-succes-1680006. php # P3jtk41b8lxhMkDK.99 The share has climbed by 31% since the beginning of the year and rebounded by 65% ??compared to its historic low of just a year ago. But it was worth more than 11 euros in February 2014. DL The board The upside is very important in case of success. It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file. The course at the time of the advice: 3.27 € More about investir.lesechos.fr/actions/conseil-... r-un-succes-1680006. php # P3jtk41b8lxhMkDK.99 DL The board The upside is very important in case of success. It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file. The course at the time of the advice: 3.27 € More about investir.lesechos.fr/actions/conseil-... r-un-succes-1680006. php # P3jtk41b8lxhMkDK.99 DL The board The upside is very important in case of success. It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file. The course at the time of the advice: 3.27 € More about investir.lesechos.fr/actions/conseil-... r-un-succes-1680006. php # P3jtk41b8lxhMkDK.99
It is now or never that we must bet on good results of the interim study concerning Livatag. We position ourselves in this sense on a naturally speculative file
4.85 +0.60 (14.12%) Vorige week te vroeg wat winst genomen.
globenewswire.com/news-release/2017/0... PARIS, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Onxeo S.A. (Euronext Paris:ONXEO) (NASDAQ Copenhagen:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced top line results from the phase III ReLive trial of Livatag® (doxorubicine Transdrug™) in adult patients with unresectable hepatocellular carcinoma (HCC), intolerant to sorafenib or having progressed after a systemic therapy including sorafenib, when compared to best standard of care. The study did not meet its primary endpoint of improving survival over the comparative group. The major reason is an unexpected high survival in the comparative group. Indeed, the study was not placebo controlled and patients in the comparative group could receive other anticancer agents (including oxaliplatin, gemcitabine or tyrosine kinase inhibitors) which might explain the high survival rate of the control arm. Livatag®, as single agent, showed a similar effect as the one observed in that comparative group with active treatments. There was no difference in efficacy between the two arms (Livatag 20mg/m² and 30mg/m²). The overall safety and tolerability profile of Livatag® in ReLive was favorable with a fully manageable toxicity profile in both groups of Livatag (20mg/m² and 30mg/m²) including in those patients who underwent the longest treatment periods, over one year. The overall tolerability was comparable to the one observed in the comparative group. “The Relive study did not meet its primary endpoint, partly due to the high survival rate in the control arm, which was unprecedented except in the most recent phase III negative trial post Sorafenib in HCC. However, Livatag tends to show a similar level of efficacy as recently reported for regorafenib in second line, in a well preserved liver function population (Child– Pugh A), although both drugs cannot be compared due to the lack of assessment of both drugs in the same trial," commented Philippe Merle, MD, Professor in Hepatology (La Croix Rousse Hospital, Lyon, France) and Coordinating Investigator of the ReLive study. ”We want to thank all the investigators who have supported the completion of this large phase III trial as well as the patients and their families, and we are confident that they benefited in participating in the Relive study.” The monitoring of the patients still enrolled in the study will continue to completion expected in H1 2019. The analysis of predefined subgroups is ongoing and the main results from the ReLive study will be presented on at the upcoming 11th Annual Conference of the International Liver Cancer Association in Seoul, South Korea (ILCA 2017 - ilca2017.org). “Once the Relive data are fully analyzed, we will reinitiate licensing discussion with potential partners based on key study outcomes to define the best path forward,” said Judith Greciet, Chief Executive Officer of Onxeo. “As already announced, Onxeo will continue to advance its diversified pipeline of innovative assets in oncology. Refocusing our R&D activities on AsiDNA™ and Beleodaq® should extend our financial visibility until early 2020." About Hepatocellular Carcinoma, an aggressive form of primary liver cancer Hepatocellular carcinoma (HCC) or hepatocarcinoma is the most common of the primary liver cancers (85% to 90%). According to Globocan (2012 data), liver cancer is the 6th most common cancer in terms of incidence (782,000 new cases worldwide each year, 5.6% of all new cancer cases) with the 2nd highest mortality rate (95% lethality) after lung cancer. The major risk factors are infection by hepatitis viruses (B and C), overconsumption of alcohol and metabolic diseases, especially non-alcoholic steatohepatitis (NASH), a growing cause of cirrhosis and HCC. About ReLive Phase III trial This international, multicenter, randomized, comparative Phase 3 trial was conducted in 11 countries (Europe, USA, and MENA) at 70 centers and enrolled 397 adult patients with unresectable hepatocellular carcinoma (HCC), intolerant to sorafenib or having progressed after a systemic therapy including sorafenib. Patients were randomized to receive Livatag® administered intravenously for 6 hours every 4 weeks (n=263) or best standard of care, i.e. any cancer therapy chosen by the physician except sorafenib (n=134). Treatment was continued until disease progression or unacceptable toxicity. The monitoring of the patients enrolled in the study will continue to completion, expected Q1 2019. Upcoming events September 16, 2017 11th meeting of the International Liver Cancer Association Oral Presentation of ReLive Results Seoul, South Korea October 2nd, 2017 French Society of Financial Analysts meeting ReLive Results & Strategic Update Paris, France October 4-5, 2017 Large & MidCap Forum Paris, France October 19, 2017 Portzamparc Biotech Symposium Paris, France October 26, 2017 Q3 results and business update
2.17 -2.04 (-48.46%) .....
www.onxeo.com/en/onxeo-announces-comp... Results demonstrate a very strong synergistic effect between AsiDNA™, first-in-class DNA break repair inhibitor (DBRi), and histone deacetylase inhibitors (HDACi) This synergy is particularly high for the combination of its two proprietary assets, AsiDNA™ and belinostat, Potential application of AsiDNA™ in combination with any HDACi fully covered by a key worldwide patent application Hopelijk kan de koers hierop weer wat herstellen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee